Feed / CTMX

CytomX Therapeutics, Inc.

CTMX

Healthcare · 3.54 -4.2% today

Participation confirmed · construction unavailableMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

CytomX Therapeutics, Inc.'s move is being confirmed by its market group.

No new filing conclusion is available. 23 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.

Company-4.2% todayVolume comparison unavailable
Market group23 of 24 activeRare Disease Biotech · active
Disclosed network0 of 7 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 16 of 24 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as XNCR begins moving with the group.

Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.

Watch this read

Who this business touches

The relationships behind CTMX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

REGNRegeneron Pharmaceuticals, Inc.partnerMar 16, 2026

A key focus of our current work with collaboration partners is T-cell engaging bispecific therapies (“TCEs”) where we have significant ongoing efforts with partners such as Bristol Myers Squibb and Regeneron and maintain significant research expertise.

ABBVAbbVie Inc.partnerMar 16, 2026

ImmunoGen (acquired by AbbVie in 2024) In December 2019, the Company entered into a License Agreement (the “ImmunoGen 2019 License”) with ImmunoGen, Inc.

Depended on by

XNCRXencor, Inc.competitorFeb 25, 2026

Other companies conducting clinical trials of CD3- or CD28-based bispecific antibodies directed to solid tumor antigens include Amgen, Astellas, Context Therapeutics Inc., CytomX Therapeutics, Inc., Genmab A/S, Immunocore Holdings plc, Janux Therapeutics, Inc…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CTMX is currently a Early Follower in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.